Core Insights - CytoDyn Inc. has secured a $30 million funding commitment from Yorkville Advisors Global to support the development of its lead product, leronlimab, which targets the CCR5 receptor and has potential applications in various cancers [1][2][3] Funding Agreement - The agreement allows CytoDyn to sell up to $30 million worth of common stock to Yorkville over the next 36 months, with CytoDyn controlling the timing of sales [2] - There are no minimum commitments or penalties for not utilizing the full amount, and the arrangement does not restrict the company's operational activities [2] Strategic Development - The funding will be used to further develop leronlimab, particularly its ability to upregulate PD-L1, providing the company with flexibility to seek additional capital through other financing or strategic partnerships [3] Company Overview - CytoDyn is a clinical-stage oncology company focused on advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor, which plays a significant role in immune function related to cancer and other diseases [4]